TREM2 and neoplasm: Thus, this therapeutic approach not only overcomes the limitations imposed by the short half-life of BsAb enabling a reduction in BsAb treatment frequency, but also the PD-1-TREM2 scFv secreted by CAR-T cells can further alleviate the immunosuppressive effects of the TME, thereby enhancing the anti-tumor efficacy of existing CAR-T cell treatment.